Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $920.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective hoisted by HSBC from $800.00 to $920.00 in a research note released on Thursday morning,Benzinga reports. HSBC currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on REGN. Citigroup increased their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Royal Bank Of Canada lifted their price objective on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Canaccord Genuity Group cut their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research report on Tuesday, May 19th. Finally, Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Tuesday, July 7th. Fourteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $802.18.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $781.49 on Thursday. Regeneron Pharmaceuticals has a 12 month low of $541.00 and a 12 month high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm has a market capitalization of $80.46 billion, a P/E ratio of 19.32, a P/E/G ratio of 1.53 and a beta of 0.20. The company’s fifty day moving average price is $754.93 and its two-hundred day moving average price is $720.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. During the same period last year, the firm earned $12.81 earnings per share. The company’s revenue was up 16.7% on a year-over-year basis. On average, research analysts anticipate that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.29%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the transaction, the executive vice president owned 12,003 shares of the company’s stock, valued at $10,291,252.17. This trade represents a 8.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at approximately $512,550. The trade was a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 4,146 shares of company stock valued at $3,432,488 in the last three months. Corporate insiders own 6.97% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in REGN. SHP Wealth Management bought a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $26,000. Western Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $29,000. Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $29,000. Finally, Trust Co. of Vermont bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $29,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: RBC said Regeneron is increasingly likely to retain key patent protection for Eylea HD, a major commercial product. Preserving exclusivity could help protect revenue and earnings from biosimilar competition. Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says
• Positive Sentiment: HSBC raised its price target on REGN to $920 from $800 and maintained a Buy rating, implying substantial upside from the referenced share price. The move signals improved confidence in Regeneron’s outlook. HSBC Raises Regeneron Price Target
• Neutral Sentiment: A reported September short-interest figure of zero shares is not actionable because it is inconsistent with normal market data and produces a zero-day short-interest ratio.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron, with a September 14 deadline for investors to seek lead-plaintiff status. The repeated notices add reputational and potential legal-cost risks, although they largely repeat the same lawsuit information rather than announce a new development. Regeneron Investor Deadline and Class Action Lawsuit
• Negative Sentiment: The lawsuit stems from the failure of a Phase 3 melanoma trial involving the Fianlimab-Libtayo therapy and allegations that Regeneron minimized statistical and protocol risks, including issues affecting progression-free-survival analysis. The trial failure reportedly erased about $11 billion in market value and raises concerns about the company’s pipeline and disclosure practices. Regeneron Clinical-Trial Risk Disclosure Lawsuit

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.